View
9
Download
0
Category
Preview:
Citation preview
WWW.PREVECEUTICAL.COM
INVESTORDECK
CSE:PREVOTCQB:PRVCFFSE:18H
SEPTEMBER14,2017
2
DISCLAIMER
Thispresentationanditsappendices(togetherthe“Presentation”)havebeenpreparedanddeliveredbyPreveCeutical™MedicalInc. (“PreveCeutical”orthe“Company”)(CSE:PREV,FSE:18H).ThePresentationanditscontentsarestrictlyconfidentialandmaynotbereproducedorredistributed,inwholeorinpart,toanyotherpersonthantheintendedrecipientwithouttheCompany’swrittenconsent.
ThePresentationispreparedfordiscussionandinformationalpurposesonly.ThePresentationdoesnotconstitute,andshould notbeconstruedas,anyofferorinvitationorrecommendationtobuyorsellanyofthesecuritiesissuedbytheCompanyanddoesandwillnotconstituteorform orbepartofanyofferingmaterial.ThisPresentationisnotmeantforandshouldnotbedistributedtoU.S.Persons(asdefinedinRegulationSofthe UnitedStatesSecuritiesActof1933,asamended)orotherwisedistributedintheUnitedStatesofAmerica.
ThePresentationcontainsinformationwhichhasbeensourcedfromthirdpartiesbelievedtobereliable,butwithoutindependent verificationbytheCompany,itsboardofdirectors,management,employees,consultants,agents,oraffiliates.ThePresentationcontainscertainforward-lookingstatementsrelatingtothepotentialbusiness,financialperformanceandresultsoftheCompanyand/orindustriesandmarketsinwhichitisormayoperate within,includingforward-lookingforecasts.Thesestatementsmaycontainwordssuchas“will”,“expects”,“anticipates”,“believes”,“estimates”andwordsofsimilarimport.Anyforward-lookingstatementsandotherinformationcontainedinthisPresentation,includingassumptions,opinions,forecastsandviews,includingthosecitedfromthirdpartysources,aresolelyopinionsandforecastswhicharesubjecttorisks,uncertaintiesandotherfactorsthatmaycauseactualeventstodiffermateriallyfromanyanticipateddevelopment.Assuchbythenatureofanyforward-lookingstatement,relyingonsuchstatementsinvolvesrisk.
ThisPresentationhasnotbeenreviewedorregisteredwithanypublicauthority,stockexchangeorregulatedmarketplace.
Byattending/reviewing/readingorreceivingthisPresentationyouacknowledgethatyouwillbesolelyresponsibleforyourownassessmentoftheinformationherein,andthemarketandthemarketpositionoftheCompanyandthatyouwillconductyourownanalysisandbesolelyresponsibleforformingyourownviewofthepotentialfutureperformanceoftheCompanyoranypotentialfutureinvestmentintheCompany.NeithertheCompany,itsmanagementorboardofdirectors,noranysubsidiaryoftheCompanyoranysuchperson’sboardofdirectors,managementoraffiliatesmakesanyundertaking,representationorwarranty(expressorimplied)astotheaccuracyorcompletenessoftheinformation(whetherwrittenororalandwhetherornotincludedinthisPresentationincludingrelatedtoanymaterialsreferredtoorotherwiseincorporatedbyreferenceherein)concerningthemattersdescribedherein.NeithertheCompanynoranysubsidiaryoftheCompanyoranysuchperson’sboardofdirectors,management,employees,consultants,agents,oraffiliates acceptsanyliabilitywhatsoeverastoanyerrors,omissionsormisstatementscontainedhereinand,accordingly,neithertheCompanynoranysubsidiaryoftheCompanyoranysuchperson’saffiliates,agents,officers,directors,employees,andconsultantsacceptsanyliabilitywhatsoeverarisingdirectlyorindirectlyfromtheuseofthisPresentationortheinformationincludedherein.
ThePresentationspeaksandreflectsprevailingconditionsandviewsasofthedatedenotedonthecoverpage.Itmaybesubject tocorrectionsandchangeatanytimewithoutnotice.NeithertheCompanynoranysubsidiaryoftheCompanyoranysuchperson’sboardofdirectors,management,employees,consultants,agents,oraffiliatesintendsto,andneitherthedeliveryofthisPresentationnoranyfurtherdiscussionswithanyrecipientshall,underanycircumstances,createanyimplicationthattheCompanyoranyoftheaforementionedpartiesassumesanyobligationtoupdateorcorrecttheinformationhereinunlessrequiredbyapplicablelaw.TheinformationinthisPresentationiscurrentasofthedateofthisPresentationnotedonitsfirstpage,and readersareencouragedtoreviewtheCompany’spublicfilingsonitsSEDARprofileon www.sedar.com.
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
PreveCeuticalMedicalInc.,ledbyanexperiencedteamofseniorexecutivesandscientists,believesthemedicalcommunityistransitioningfromasystemwhich“fixedpeopleaftertheybecomeill”tooneofprecision,preventivebased,medicine.
Withthisfocus,PreveCeutical iscommittedtobecomealeaderinpreventivehealthsciences.
3
WHATWEBELIEVE
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
2016 2017 2018 2019
4
CurrentResearch&DevelopmentPrograms
Research&DevelopmentPartner
CurrentHomeopathicMedicines&Supplements
Natural&SyntheticPeptidesderivedfromBlueScorpion Venom.
Dualgene therapyforDiabetes &Obesity
What’snext?
Sol-gelplatformfortime-released,nose-to-braindeliveryofCBDs.
Pre-clinicalupfrontlicensingagreements.
What’snext?• Internationaldistribution
agreements• Productextensions• Marketingpartnerships
CELLB9®• Developed• Trademarked
DigitalMarketingprogramcommences.
TherapeuticProductJointVenture
WHATWEAREUPTO
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
R&DPROGRAMSATAGLANCE
5
PEPTIDERESEARCHPROGRAM• Identificationofpeptides• Synthesisandstabilization
SOL-GELDELIVERYPLATFORM• Analysisofplant-derivedCBDs• FormulationofCBDinfused
soluble-gels• Performdeliverystudies
DUALGENETHERAPY• Rationaldesignoftissuetargeted
bio-responsivegenedeliverysystems• Systematicevaluationtowardsgene
andproteinsilencinginappropriatemodels–multiplephasesCurativetherapyfordiabetes&obesity
2017 2018 2019 2020
PartneredResearchandDevelopmentprogramswithUniQuest,themaincommercialisationcompanyfortheUniversityofQueensland.Undertheagreements,intellectualpropertyarisingfromthecarryingoutof,resultsdevelopedduring,orcreatedbytheprogramswillbeownedbyPreveCeutical.
*Collaborators:QIMRBerghofer– ProfessorGrantRammandMurdochUniversity– Dr RakeshVeedu.
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
ResearchandDevelopmentProgramsTimeline
PEERCOMPARISONS
6CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
COMPANYVALUATIONS&PIPELINES
SmallMolecule/Peptides
DrugDeliveryCBDs
GeneTherapy
PRE-CLINICAL PHASEI PHASEII PHASEIII NDA
Genmab
AximBiotech
GWPharmaceuticals
Novartis
Drug:MedChew-1401 (Chewinggum)•ProposedIndication:MultipleSchlerosis/PainSpasticity2
MarketCap:USD14Billion1SharePrice:USD$2351CPH:GEN
MarketCap:USD332Million2SharePrice:USD$6.332OTCQB:AXIM
MarketCap:USD2.7Billion5SharePrice:USD$107.095NASDAQ:GWPH
MarketCap:USD224Billion6SharePrice:USD$85.706NYSE:NVS
DrugName:Tisotumab vedotin (HuMax®-TF-ADC)•ProposedIndication:solidtumours (ovary,cervix,endometrium,bladder,prostate,head&neck,esophagus,lung1
Drug:GWP42006(CBDV)•ProposedIndication:Epilepsy3
Drug:CTL019(Tisagenlecleucel – chimericantigenreceptor-T”CAR-T”)•Indication:Relapsed/RefractoryB-cellacutelymphoblasticleukemia4
COMPANY/INDUSTRY
1 http://www.genmab.com/- SharePriceDate– September08,20172http://aximbiotech.com - SharePriceDate- September08,20173https://www.gwpharm.com/products-pipeline5http://www.nasdaq.com/symbol/gwph - SharePriceDate- September08,20174http://www.ajmc.com/newsroom/novartis-car-t-therapy-ctl019-approved-10-0-by-fdas-odac6 https://www.google.com/finance?q=NYSE:NVS- SharePriceDate– September08,2017
7
DevelopingnatureidenticaldrugsderivedfromBlueScorpion Venomthattreat,regulateandpreventcancerprogression.Precisiontreatmentsforearlystagetumorsandmetastaticlesions.
Theglobalmarketforcancertreatments$107Bnin 20151Projections– $161.30Bn by2021. 2
Dual-gene therapyfordiabetesandobesity.Proofofconcepthasalreadybeendemonstrated –based on5yearsofresearch,targetinga singlediabetesandobesitycausinggene.
2016globalexpenditureforDiabetesUSD$825Bn. 5Globaltype2diabetesmarketsettoreach$58.7 Bn. 6
DrugdeliverytechnologymarketUSD$1,669.40Bnby2021. 3GlobalneuropathicpainmarketUSD$8.3Bnby2024. 4
Sol-gel nose-to-brain deliverysystem,forCBDs,toprovideclinicalreliefacrossarange ofindicationsfrompain,inflammation,seizuresandneurologicaldisorders.
MEETINGCURRENTUNMETNEEDS
MARKETOPPORTUNITIES
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
1http://www.imshealth.com/en/about-us/news/ims-health-study-global-market-for-cancer-treatments-grows-to-107-billion-in-2015-fueled-by-record-level-of-innovation2https://globenewswire.com/news-release/2017/07/03/1037328/0/en/Global-Cancer-Drugs-Market-Size-Share-Will-Grow-USD-161-30-Billion-by-2021-Zion-Market-Research.html3http://www.marketsandmarkets.com/PressReleases/drug-delivery-technologies.asp4http://www.prnewswire.com/news-releases/global-neuropathic-pain-market-to-reach-us-83-bn-by-2024-end-developing-economies-expected-to-fuel-revenue-growth-603764096.html5https://www.hsph.harvard.edu/news/press-releases/diabetes-cost-825-billion-a-year/6http://www.drug-dev.com/Main/Back-Issues/Global-Type-2-Diabetes-Market-Set-to-Almost-Double-1140.aspx
8
Ourpre-clinicalprogramsareledbyDr.MakJawadekar (CSO),having28years’experiencewithPfizerInc., mostrecentlyasPfizer’sDirectorof PortfolioManagement.Dr. Jawadekar’sexperiencewithexternalpartnershipsandalliancesforresearchanddrugdevelopmentwillbeintrumentalforallofourResearchPrograms.
Mak JawadekarPh.D.- ChiefScienceOfficer
Specialties:R&D,ExternalAllianceManagement,Contracting,Outsourcing,Benchmarking,DrugDeliverySystemsassessment,Formulations,ClinicalSupplyMfg andPackaging,CTM,Pharmaceutics,PharmSciences,PerformanceMetricsevaluationsandassessment,AsiaR&D,ExtensiveNetworksintheUS,EU,IndiaandotherpartsofAsiaincludingJapanandChina.
RESEARCHTEAM
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
Dr.Harendra (Harry)Parekh,Ph.D,BSc.HonsI– ChiefResearchOfficer
BasedattheUniversityofQueensland’s(UQ)PharmacyAustraliaCentreofExcellence(PACE),Dr ParekhalsoholdsadjunctpositionsattheNationalUniversityofSingapore,andManipal University,India.Dr ParekhheadstheDrug/GeneDeliveryGroupatPACE-UQwithhisteamdevelopinghighlyinnovativeandtranslationalmedicinedeliverysystemsin-conjunctionwithphysicianswhoseexpertisespancancer,diabetes-&-obesity,maculardisease,infectiousdiseaseandtraditional(Chinese)medicine.
9
RESEARCHTEAM
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
Dr.RakeshVeedu isleadingthePrecisionNucleicAcidTheranostics group,asaMcCuskerResearchFellowwiththePerron InstituteforNeurologicalandTranslationalScience,basedatthe andCentreforComparativeGenomicsatMurdochUniversity(Perth,Australia).He,isanemergingexpert,nationallyandinternationally,inthefieldofmolecularmedicine.Heisusingnucleicacid-basedbiotechnologiesanddevelopingnovelnucleicacidaspotentialdrugtherapiesforarangeofneurologicaldiseases,geneticdisordersandsolidcancers.
ProfessorGrantRamm iscurrently theheadoftheHepaticFibrosisLaboratoryandCoordinatoroftheCellandMolecularBiologyDepartmentatQIMR-Berghofer,a leadingmedicalresearchinstitutelocatedin Brisbane,Australia.
10
RESEARCHCOLLABORATORS
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
11
PreveCeutical’s scientistswillusepropietary chemistrytogenerateNatureIdentical™peptides,consistingofalibraryofmodifiedpeptideanalogues,whichwillthenbetestedindiseasemodels.
Currentlyunderway,phaseone(ofthreedistinctphases)tofirstidentifyscorpionvenom-basedpeptides/proteins.
TheCaribbeanBlueScorpion(Rhopalurus junceus)venomisextremelyrichinavarietyofproteins,whichabnormalcellsconsume.Abnormalcellsemitauniqueelectrostaticchargethatattractstheproteininthevenom.
NATUREIDENTICAL™PEPTIDERESEARCHPROGRAM
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
§ Developingnatureidenticaltherapiesderivedfrom,naturalcompounds,startingwithBlueScorpionVenom,totreat,regulateandpreventcancerprogression.
§ Retainkeybeneficialproperties,soreplicatingthesynergiesthatnaturebringsallowingforconsistencyandefficacyinmassproduction.
§ One-stepsynthesis.
§ Effectivelymanufactureasmuchoftheproductasthemarketdemands.
PEPTIDER&DPROGRAM
12
Peptidesarecurrentlybeingusedtotargetanarrayofdiseaseindicationsincludingmetabolicdisorders,pain,cancers,cardiovascularandinfectiousdiseases.Thetherapeuticpeptidemarketisexpectedtoundergoanexpansionintheforeseeablefuture.
ThePeptideResearchandDevelopment(“R&D”)involvespeptidelibrarysynthesis,pharmacologicalevaluation,alongsidepharmacokineticassessmentandefficacydeterminationsinappropriateanimalmodelsofpainandinflammation.Thismayencompasseitherparty’sintellectualpropertyandproductlineandotherpharmaceuticalofferingsthatmayfallwithinthepeptideR&Dprogram.
AteamledbyDr.Parekhin-conjunctionwithfellowcollaboratorsatTheUniversityofQueensland(UQ)proposetoexpandtheuseoftheirdisulfidelinkertechnologytodevelopnon-addictiveanalgesicsformoderate-to-severepain.
PreveCeutical andUniQuest arecurrentlynegotiatingandpreparingthedefinitiveagreementregardingthecollaboration.
NON-ADDICTIVEANALGESICS
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
13
Developingthefirstnose-to-braindeliverysystemofCannabinoids(CBDs)
§ Provideclinicalreliefacrossarangeofindicationsfrompain,inflammation,seizuresandneurologicaldisorders.
§ Proprietaryformulationintendedfordeliveryviaanasalspray.
§ Extendedreleaseusingnanobubble technologytoallownormallife-style.
§ Universally-patientfriendly,meaningformulationsthatcanbeusedinchildrenandadultsalike.
Patentability
§ Anovelprocessforpreparinginsolubledrug-containingnanomicellesandtheirsuccessfulincorporationintosol-gelshasbeendevelopedintheParekhgroupatPACE-UQ.
§ Uniquest,UQ’stechtransfercompany,reviewedalldatainlate-Feb2017.ThePatentReviewCommitteeapprovedthefilingofaprovisionalpatentapplicationaroundthesinglephasesol-gelsfornasaldelivery.
SOL-GELDELIVERYPLATFORM
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
14
PreveCeutical isworkingwithfourleadingAustralianresearchcenterstoco-developapotentialcurefordiabetes&obesity.
DUALGENETHERAPYFORDIABETES&OBESITY
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
15
PreveCeutical iscommencingground-breakingresearchtargetingagenetherapy“curefortype-2diabetesandobesity.”BytakingagenesilencingapproachbyselectivelytargetingthegenethatencodesfortheproteinPTP-1B,reducingPTB-1Bproteinlevels,therebyreducingcapacitytostorefat,reversingobesity,fattyliverdiseaseetc.
Engineerapanelofnovel,ligand-targetedbio-responsivegenecarrier-&-releasesystems.
Re-synthesizeapanelofSmart-siRNAconstructingagainstthegeneimplicatedandover-expressedinbothtype-2diabetesandobesity
EvaluatesiRNA-bioresponsive carriercomplexesingeneandproteintargetingusingin-housederivedcellularmodelsofdiabetesandobesity,includingtoxicitystudies
Performbiodistribution studiesofleadsiRNA-carriercomplexesfocusingontheliver,skeletalmuscle,fatandbrainofhealthymice.
Performgene-proteinsilencingefficacyandsafetyevaluationstudiesinobese-diabeticandlean-diabeticmicewithourleadSmart-siRNAbio-responsivecarriersystems.
ABOUTTHEGENETHERAPYDEVELOPMENTPROGRAM
2017 2018 2019 2020
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
16
KILLSONEPERSONEVERYSIXSECONDS12015GLOBALEXPENDITUREUSD$673Bn 2040PROJECTIONSUSD$802Bn1LOSSESINGDPWORLDWIDEFROM2011– 2030USD$1.7TRILLION2
2http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf
Estimatednumberofpeoplewithdiabetesworldwideandperregionin2015and2040(20-79years)1
NorthAmericaandCaribbean1201544.3million204060.5million
Europe1
201559.8million204071.1million
FACTS&FIGURES
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
DIABETES:
1http://www.diabetesatlas.org/
MiddleEastandNorthAfrica1
201559.8million204071.1million
Africa1
201514.2million204034.2million
SouthEastAsia1
201578.3million2040140.2million
WesternPacific12015153.2million2040214.8million
SouthandCentralAmerica1
201529.6million204048.8million
• Currentlyprescribedantidiabeticdrugtherapiesuniversallyaimtoreducebloodglucoselevelsbytargetingoneormoreofthesixkeyorgans/tissues,i.e.thepancreas,liver,skeletalmuscle,smallintestine,kidneys,andfatty tissue.
• AllofthecurrentlyavailableagentsusedtomanagediabeteshaveshownNOcapacitytohalttheprogressivedeclineofpancreaticβ-cellfunction– thecellsthatgenerates insulin!
• Conventionalagentsarealsolimitedbytheirunacceptablesideeffectsandadversesafetyprofile.
• AttemptstoBLOCKtheproteinusingconventionaldrugshasfailedduetoanarrayofunacceptablesideeffectsandsafetyissues.SeeChemicalReviewsarticle:http://pubs.acs.org/doi/abs/10.1021/cr5002832
17
• Ourdualgenetherapyapproachtargetsakeyprotein(PTP-1B)implicatedandover-producedbythekeyinsulinsensitiveorgansindiabetesandobesity– liver,fattytissue,skeletalmuscleandthebrain.
• OurgenesilencingapproachwouldselectivelytargetthegenethatencodesfortheproteinPTP-1BONLY,itisHIGHLYselective.
• ByreducingPTP-1Bproteinlevels,cellsinthekeyorganswouldhavereducedcapacitytostorefat,reversingobesity,fattyliverdisease,etc.
• ByreducingPTP-1Bproteinlevels,cellsignalingpathwaysthatpromoteglucoseuptakewouldbere-activatedandinsulinresistanceovercome.
CURRENTDRUGTHERAPIESVS.GENETHERAPY
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
DIABETES:
18
AIM5:
AIM2:
AIM3:
AIM4:
AIM1:
Themulti-disciplinaryteamhavemappedthenextphaseoftheproject,whichspans4years,andencompasses5keyaims.
Engineerapanelofnovel,ligand-targeted(i.e.liver,skeletalmuscle,fattytissueandbrain)bio-responsivegenecarrier-and-releasesystems.
Re-synthesizeapanelofSmart-siRNAconstructsagainstthegeneimplicatedandover-expressedinbothtype-2diabetesandobesity.
EvaluatesiRNA-bioresponsive carriercomplexesingeneandproteintargetingusingin-housederivedcellularmodelsofdiabetesandobesity,includingtoxicitystudies.
Performbiodistribution studiesofleadsiRNA-carriercomplexesfocusingonliver,skeletalmuscle,fattytissueandbrainofhealthymice.
Performgene-proteinsilencingefficacyandsafetyevaluationstudiesinobese-diabeticandlean-diabeticmicewithourSmart-siRNAbio-responsivecarriersystems.
TOPRECLINICALEVALUATION
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
THENEXTPHASETHROUGH
19
WARRENMOON- PRESIDENT DAVIDMELTZER- CEO
JOINTVENTUREWITHSPORTS1 MARKETING
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
JointVentureestablishedtodevelopatherapeuticproductsgearedtowardsathleteswhosufferfromconcussions(MildTraumaticBrianInjuryorTBI).
PreveCeutical andSports1MarketingbelievethatthereistherapeuticpotentialinthepeptidesandproteinsconnectedtotheCaribbeanBlueScorpionvenomtopotentiallytreatconcussions.
• 2010’sestimatedeconomiccostsofconcussionsis$76.5Bn,ofthis,90%arefatalconcussions. 1
• Hundredsofthousandsofheadtraumas,includingundiagnosedconcussionsgounreportedanduntreatedeachyear. 2
• Undiagnosedbraininjuriesareamajorcauseof depression, anxiety,drug,alcoholabuse,homelessness, ADD/ADHD andsuicide. 2
2AmenClinics;http://www.amenclinics.com/conditions/brain-injury/1CentersforDiseaseControlandPrevention;https://www.cdc.gov/TraumaticBrainInjury/index.html
THERAPEUTICPRODUCT- TBI
20
StephenVanDeventer - Chairman&ChiefExecutiveOfficer
Mr.VanDeventerisanexperiencedbusinessmanandcorporatedirector.Specializingininternationalcorporaterelationsandbusinessdevelopmentoverthelasttwentyfiveyears,Mr.VanDeventerhasfocusedonlaunchingsmalltomediumsizedcompaniesintothepublicmarketsinCanada,theUnitedStatesandEurope.Hehasalsoownedandoperatedprivatecompanies.
KimberlyVanDeventer- President&Director
Ms.VanDeventerisanentrepreneurwithasuccessfultrackrecordofaccomplishmentthatshebringstoPreveCeutical.Motivatedanddetermined,shewasrankedthethirdhighestgrossingfemalebusinessownerinBC,Canadain2009.Kimisadrivingforcebehindthebusinessandisunwaveringinhercommitmenttobringawarenessofhealthanddiseasepreventiontopeople everywhere.
BrianHarris- V.P.CorporateDevelopment&Director
Mr.HarrisisManagingPartneratMarketingServicesInternational.BrianHarrisservedasaDirectorandCEOofRussellBreweriesInc.,aTSX-VlistedCompany.Duringhistenyeartenure,RussellwasoneofthefastestgrowingcompaniesinCanada.PriortothathewasaDirectorandSVPforEFTechLtd.,apubliccompanylistedontheASXandaleadingsupplierofElectronicFundsTransferservicesinAustralia.AfounderofBASS(BestAvailableSeatingService)International,thecomputerticketingsystemwhichoperatedin12marketsand4continentsnowknownas TicketMaster.
LEADERSHIPTEAM
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
21
ShabiraRajan,MBA,CPA,CGA - ChiefFinancialOfficer&Controller
Ms.Rajanisaseniorfinancialexecutivewithover20yearsofexperience,leadingthefinancialdisciplineforsuccessfulbusinessesinbothprivateandpublicsectors.Shehasatrackrecordofprovidingleadershipforstrategicvaluecreationandcontinuousimprovement,aswellas,providingeffectivedirectionto organizationsonissuesrelatingtocorporategovernance,financialoversightandriskmanagement.Oneofherleadershiproleswasthatof DirectorofFinanceatCanadaLineRapidTransitInc.,whichplanned and constructed a $2billion rapid transit system inmetro-Vancouver, on time andwithin budget.
GregS.Reid-Director
FilmmakerandKeynoteSpeakerGregS.Reidisa#1best-sellingauthor,entrepreneur,andtheCEOofseveralsuccessfulcorporations,whohasdedicatedhislifetohelpingothersachievetheultimatefulfillmentoffindingandlivingalifeofpurpose.Inadditiontobeingpublishedinover35booksandfeaturedonNationallySyndicatedprogramsacrosstheU.S.,heisalsothecreatorandproducerontheInternationalacclaimedfilmsPassItOn,andThreeFeetFromGold.*(ListedonIMDB)
MattColtura-Director
Mr.Coltura isinthefinalyearoftheBBA,withfinanceoption,atOkanaganCollege.Hehasbeeninthefinanceindustryfor3years.Currently,Mr.Coltura istheCFOofCayenneCapitalCorpandsitsontheboardofdirectorsforStoneridgeExplorationandCarreraExploration.
LEADERSHIPTEAM
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
22
MakJawadekarPh.D.- ChiefScienceOfficer
Dr.MakJawadekarworkedatPfizerInc.inGroton-NewLondon,Connecticut,for28consecutiveyearsmorerecentlyasaDirectorofPortfolioManagement.HewasresponsibleforDrugDeliveryTechnologyAssessmentfunctioninvolvingexternal‘DrugDelivery’technologies.Hehasextensiveexperienceincreatingandcultivatingexternalpartnershipsandalliancesfordrugdeliverytechnologies.HebeganhisprofessionalcareeratPfizerCentralResearchinearly1982,afterhavingcompletedhisPh.D.inPharmaceuticsattheUniversityofMinnesota.
HarryParekh.Ph.D,BScHonsI - ChiefResearchOfficer
BasedattheUniversityofQueensland’s(UQ)PharmacyAustraliaCentreofExcellence(PACE),DrParekhalsoholdsadjunctpositionsattheNationalUniversityofSingapore,andManipal University,India.Dr ParekhheadstheDrug/GeneDeliveryGroupatPACE-UQwithhisteamdevelopinghighlyinnovativeandtranslationalmedicinedeliverysystemsin-conjunctionwithphysicianswhose expertisespancancer,obesity-&-diabetes,maculardisease,infectiousdiseaseandtraditional(Chinese)medicine.
NicoleGoncalves-Krysinski - ChiefLegalOfficer
NicoleGoncalves-Krysinski,Esq.,isanattorneyandapartnerinherownlawfirminNewYorkCity,NewYork.ShehasatJ.D.fromSt.John’sUniversityandB.A.fromU.C.L.A.Nicolepracticesinbothstateandfederalcourtshandlingawiderangeofcasesincludingcomplexbankruptcymatters,matrimonialandcriminaldefenselitigation.Herareasofpracticealsoincludecontractnegotiations,businessandtransactionallawandcorporate advisement.
LEADERSHIPTEAM
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
23
AliciaRebman– VPMarketing&Advertising
Ms.RebmanisaMarketingprofessionalwithabackgroundinPublishingTechnologies,CommunicationsandGraphicDesign;specialtyinbranding&communicationsforsocialenterpriseandNGOstart-ups.Ms.Rebmanranasuccessfuldesignservicescompanyfor6yearsandthenelevatedtoheadthemarketingdepartmentfortheGlobalofficeofHartley&MarksGroup,aninternationaldesign&publishingcompany.
SusanBlond– DirectorofPublicity
SusanBlondstartedhercareerpaintingwithTheWhitneyMuseumstudioprogrambutonceshegotajobatAndyWarhol’sInterview,lifewastooexcitingtopaint.Shesoldadsthereprimarilytorecordcompaniesandthemagazinetookoff.ShethenwentontoUnitedArtistsandEpic/CBSRecordswhereshebecamethefirstwomanVPinthewholeindustry.TheartistssherepresentedwereMichaelJackson,BoyGeorge,Sade,theClash,Ozzy Osbourne,CultureClub,CyndiLauper,Sade,MeatLoaf,Boston,LutherVandross,TheClashandcountlessothers.SheformedSusanBlondInc.in1986wheresherepresentedJamesBrown,Prince,DavidBowie,Usher,JulioIglesias,SpiceGirls,GeorgeJones,TheSpiceGirls,andMorrissey,andcompaniessuchasTheHardRockCafe,SportsClubLA(nowEquinox)andexecutiveslikeCharlesKoppelman andCliveDavis.SusanservesasSecretaryoftheBoardofDIFFA:DesignIndustriesFoundationFightingAIDS.
LEADERSHIPTEAM
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
SydneyCole- ExecutiveAssistant&OfficeManager
Ms.ColehasheldAdministrationSupportandtrainerroleswithintheHospitalityIndustryforsevenyears.Ms.ColehasalsoworkedforaVentureCapitalcompanyforfiveyearsasanexecutiveassistantandofficemanager.FrombookkeepingtoeventcoordinationMs.Cole’sorganizationandfortitudekeepoperationsrunning smoothly.
DeannaKress- DirectorofCorporateCommunications&InvestorRelations
Ms.DeannaKresshasbeeninvolvedinpubliccapitalsince2003withafocusonInvestorRelationsandCorporateCommunications.Ms.Kresshaswide-rangingexperiencewithanumberofexplorationandproductioncompanieslistedonboththeTSXVentureExchangeandtheTorontoStockExchange.Ms.Kressledvariousmarketinginitiativeswithpublicandprivatecompanymanagementteamstoassistwithequityfinancing's,tosecurecoveragefromallsectorsoftheinvestingcommunity andtoimplementinternalprocedurestoensureclearandeffectivecommunicationtostakeholders.Ms.KressholdsaMedicalDiplomaandisintheprocessofcompletingaHealthSciencesDegree.
24
LEADERSHIPTEAM
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
RyanVanDeventer– BusinessDevelopmentMr.VanDeventeriscurrentlyfinishinghisstudiesforComputerInformationSystems,InformationTechnologyatKwantlenPolytechnicUniversity. TrainingunderMr.VanDeventerSenior, Mr.VanDeventerjunior’sambitionsfindhimtobeaneagerfinance professional.
25
•PublicListing Advisor• Investmentbanking advisor•CEOofachemical company•COOofawireless company
• Sales&marketing•Product Development•PR& Communications•MercedesBenz finance•Dawsongroup PLC• InstituteofPublic Relations
•30+yearsBusiness Development•Business&Finance Law•Commodity Broker•Arts&Antiquities Trader•RealEstate– Prime Properties
•20yearsCorporate Strategy•575+startup consulting•Mergers& Acquisitions•BusinessDevelopmentBankof Canada• Investment Strategy
IsaacMossIsaacMossB.Sc,M.Pub.Admin.has30yearsofexperienceininternationalcorporatefinance,publicmarketsandbusiness.IsaacwasassociatedwithanadvisorygroupinGenevaSwitzerland,providingstrategicandcorporatefinanceadvisoryservicestoanumberofclientcompaniesaroundtheglobeindiverseindustriesrangingfromminingandenergy,forestproducts,technology,telecommunicationsandbiotechnology,andthehospitality industry.
RuthHenderson
Ruthhaslaunchednewproductssuccessfullyintonewandexistingmarkets,increasedprofitandmarketshareusingbothlargeandsmallbudgets– bothnationallyandinternationally– andmanagedbothinhouseandagencyworkers.Herexpertiseincludesstrategicplanning,sales,businessdevelopmentandproductdevelopment.Askilledcommunicatorandnegotiatorwithinterpersonalskillsthatincludestrongpartnerandcustomer relationships.
IanSpencer
Ianhasbeenaserialentrepreneurfromhismid20'shavingworkedinthefinanceindustryworkingasacommoditybrokerincentralLondon.IanstudiedBusinessandFinanceLawatBrunelUniversity,London,butchosecommercialtradingashispassionwasfordealingartandantiqueswhichhewasextremelysuccessfulat.
WandaHalpert
ThefounderandDirectorofConcordBusinessDevelopment,WandaHalpertisaveteraninthestrategicplanningindustry.Shehasdeliveredpresentationsontheessentialsofbusinessplanningtopubliccompanyforumsandfederallyfundedmanagementprogramsanddirectedtheproductionsofover500advancedbusinessplansindozensofindustrysectorsforbothprivateandpubliccompanies.
ADVISORYBOARD
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
26
PARTNERS
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
27
OurVision
OurVisionistobealeaderinthepreventivehealthsciencesbringinginnovativeoptionsforpreventiveandcurativetherapiesultilising organicandnatureidenticalproducts.
KeystoSuccess
Managementwithextensiveresearchexperience,productdevelopmentexperience,deepcorporatestrategyandcapitalmarketsleadership.Partneringwithleadingindustryexpertsandcompanies.
SUMMARY
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
28
PLEASECONTACT
StephenVanDeventerChairman&CEOCell:1(604) 306-9669Office:1(604)416-7777ext.6230steve@preveceutical.com
DeannaKressDirectorofCorporateCommunications&InvestorRelationsCell:1(778)999-6063Office:1(604)416– 7777ext.6288deanna@preveceutical.com
CSE:PREV|OTCQB:PRVCF|FSE:18HWWW.PREVECEUTICAL.COM
Recommended